Hanall Biopharma announced on the 23rd that it will suspend manufacturing of its licensed items (pharmaceutical manufacturing) for the next three months.
The manufacturing suspension is in line with the confirmation of the administrative disposition issued by the Ministry of Food and Drug Safety to Hanall Biopharma in May of last year.
The administrative disposition period is from November 24, 2021 to February 23, 2022. The target of manufacturing suspension is Hanall Biopharma's own approved products.
The amount of business suspension was 14.3 billion won, which is 13.2% of the total sales in 2019.
Reporter Lee Ji-sun stockmk2020@gmail.com
저작권자 © 인포스탁데일리 무단전재 및 재배포 금지
